Pieris Pharmaceuticals, Inc. Forecast, price target & analysts
Pieris Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Pieris Pharmaceuticals, Inc. Classifications & Recommendation:
Pieris Pharmaceuticals, Inc. Price Target
| Target Price | $49.25 |
| Price | $26.97 |
| Potential |
82.61%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Pieris Pharmaceuticals, Inc. 2026 .
The average Pieris Pharmaceuticals, Inc. target price is $49.25.
This is
82.61%
register free of charge
$70.00
159.55%
register free of charge
$38.00
40.90%
register free of charge
|
|
| A rating was issued by 8 analysts: 8 Analysts recommend Pieris Pharmaceuticals, Inc. to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Pieris Pharmaceuticals, Inc. stock has an average upside potential 2026 of
82.61%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2029
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 42.81 | 0.03 |
| 65.29% | 99.94% | |
| EBITDA Margin | -32.84% | -59,743.84% |
| 79.09% | 181,808.52% | |
| Net Margin | -67.22% | -11,600.39% |
| 63.25% | 17,157.88% |
8 Analysts have issued a sales forecast Pieris Pharmaceuticals, Inc. 2024 . The average Pieris Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Pieris Pharmaceuticals, Inc. 2024 . The average Pieris Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Pieris Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2024. The average Pieris Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2029
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -21.80 | -2.23 |
| 39.26% | 89.77% | |
| P/E | negative | |
| EV/Sales | 11,663.45 |
3 Analysts have issued a Pieris Pharmaceuticals, Inc. forecast for earnings per share. The average Pieris Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Pieris Pharmaceuticals, Inc....
Current Pieris Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 01 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | Mar 26 2025 |
| Jones Trading |
Locked
➜
Locked
|
Locked | Mar 25 2025 |
| Scotiabank |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Feb 20 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 11 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 01 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
Mar 26 2025 |
|
Locked
Jones Trading:
Locked
➜
Locked
|
Mar 25 2025 |
|
Locked
Scotiabank:
Locked
➜
Locked
|
Mar 07 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Feb 26 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Feb 20 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 11 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
